5-alpha-reductase inhibitors are a group of drugs that are used in the treatment of an enlarged prostate gland (benign prostatic hyperplasia) and male pattern hair loss.
Drugs in this class are finasteride (marketed as Proscar [finasteride 5 mg] and Propecia [finasteride 1 mg]) and dutasteride (marketed as Avodart). Dutasteride is also available in combination with tamsulosin, under the brand-name Jalyn.
To report any serious adverse events associated with the use of these drugs, please contact the FDA MedWatch program using the contact information at the bottom of this page.
Questions and Answers: Finasteride Label Changes[ARCHIVED] FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer[ARCHIVED]
Questions and Answers: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer[ARCHIVED]
December 1, 2010: Oncologic Drugs Advisory Committee Meeting Announcement[ARCHIVED]